A 25-year Experience at an Academic Medical Center in the United States: Are There Racial Disparities in the Prognosis of Patients Diagnosed With Hypopharyngeal Carcinoma?

hypopharyngeal carcinoma racial disparities

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
03 Nov 2020
Historique:
entrez: 7 12 2020
pubmed: 8 12 2020
medline: 8 12 2020
Statut: epublish

Résumé

Introduction This study attempted to identify disparities in outcomes between African American (AA) and Caucasian American (CA) patients treated for hypopharyngeal carcinoma at a tertiary care institution over the past 25 years. Methods An institutional review board (IRB)-approved and Health Insurance Portability and Accountability Act (HIPPA)-compliant retrospective analysis was performed on patients with squamous cell carcinoma of the hypopharynx treated at our institution between January 1994 and December 2018. Data regarding demographics, stage, treatment, and follow-up were collected. Outcomes, including median survival and overall survival, were calculated using the Kaplan-Meier method. All analyses were performed using the Social Packages for the Social Sciences (SPSS) v. 24 (IBM Corp., Armonk, NY). Results We identified 144 hypopharyngeal carcinoma patients who were treated during this period. Our patient cohort consisted of 61.8% AA and 35.4% CA (P=0.538). Overall, 96% of them presented at an advanced stage (Stages III & IV) of the disease, and only 4% presented in the early stages (Stages I & II). There was no significant difference between AA and CA patients who presented with advanced disease (96.6% vs. 94.1%). In our patient cohort, 15.3% of patients did not receive any therapy; however, 51.4%, 22.9%, and 10.4% of them underwent definitive chemoradiotherapy, definitive surgery, or palliative chemotherapy, respectively. There were no significant differences in patient racial proportions within each treatment group. The median follow-up of the entire cohort was 13 months. There was no significant difference between the median survival of AA and that of CA patients (16 months vs. 15 months; p=0.917). Moreover, there was no significant difference in the overall survival between AA and CA patients at three years (27.2% vs. 36.3%; p=0.917) and five years (20.4 % vs. 16.7 %; p=0.917). Conclusions A retrospective review of patients with hypopharyngeal cancer treated at our institution over the previous 25 years did not identify significant racial disparities regarding the stage at presentation or prognosis. This study suggests that when patients have equal access to care, they appear to have a similar prognosis despite racial differences. Further studies are needed to validate this hypothesis.

Identifiants

pubmed: 33282583
doi: 10.7759/cureus.11306
pmc: PMC7714743
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e11306

Informations de copyright

Copyright © 2020, Vengaloor Thomas et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Head Neck. 2011 Aug;33(8):1092-8
pubmed: 20967872
J Am Dent Assoc. 2006 Feb;137(2):203-12
pubmed: 16521387
Eur Arch Otorhinolaryngol. 2018 Jan;275(1):181-189
pubmed: 29080963
Otolaryngol Head Neck Surg. 2011 Mar;144(3):381-9
pubmed: 21493200
Hippokratia. 2009 Jul;13(3):154-60
pubmed: 19918303
Acta Otorhinolaryngol Ital. 2013 Oct;33(5):299-306
pubmed: 24227894
Acad Pediatr. 2013 May-Jun;13(3):191-203
pubmed: 23680339
Cureus. 2020 Jan 16;12(1):e6679
pubmed: 32104619
Popul Res Policy Rev. 2017 Apr;36(2):181-201
pubmed: 28366968
Head Neck. 2016 Apr;38(4):564-72
pubmed: 25488341
Int J Cancer. 2005 May 1;114(5):806-16
pubmed: 15609302
Cancer Med. 2018 Dec;7(12):5889-5900
pubmed: 30479063
Surg Oncol Clin N Am. 2012 Jul;21(3):417-37, viii
pubmed: 22583991
Cancer Prev Res (Phila). 2019 Apr;12(4):255-270
pubmed: 30777857
Laryngoscope. 2019 Mar;129(3):643-654
pubmed: 30152118
J Cancer Educ. 2015 Sep;30(3):546-51
pubmed: 25398667
BMC Cancer. 2017 Dec 29;17(1):904
pubmed: 29284434

Auteurs

Toms Vengaloor Thomas (T)

Radiation Oncology, University of Mississippi Medical Center, Jackson, USA.

Kati Krishna (K)

Radiation Oncology, University of Mississippi Medical Center, Jackson, USA.

Hiba Z Ahmed (HZ)

Radiation Oncology, University of Mississippi Medical Center, Jackson, USA.

Eswar Mundra (E)

Radiation Oncology, University of Mississippi Medical Center, Jackson, USA.

Anu Abraham (A)

Pathology, University of Mississippi Medical Center, Jackson, USA.

Eldrin Bhanat (E)

Orthopaedic Surgery, University of Mississippi Medical Center, Jackson, USA.

Mary R Nittala (MR)

Radiation Oncology, University of Mississippi Medical Center, Jackson, USA.

Satya Packianathan (S)

Radiation Oncology, University of Mississippi Medical Center, Jackson, USA.

Srinivasan Vijayakumar (S)

Radiation Oncology, University of Mississippi Medical Center, Jackson, USA.

Classifications MeSH